US FDA Accepts for Review Biohaven ' s New Drug Application (NDA) Filing of Intranasal Zavegepant for the Treatment of Migraine

If approved, zavegepant nasal spray would be the only FDA-approved CGRP receptor antagonist in an intranasal formulation, giving patients a new treatment option that provides ultra-rapid pain relief in as little as 15 minutes that lasts...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news